Screener
Climb Bio, Inc. CLYM Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(13,722) | $(20,781) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 1,605 | 2,022 |
| Non-cash operating lease expense | 58 | 39 |
| Accretion of discounts on marketable securities, net | (305) | (669) |
| Depreciation and amortization expense | 38 | — |
| Unrealized foreign currency transaction loss | 21 | 24 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s stock-based comp?
- Climb Bio, Inc. (CLYM) reported stock-based comp of $1.61M in Q1 2026.
- How has Climb Bio, Inc.'s stock-based comp changed year-over-year?
- Climb Bio, Inc.'s stock-based comp decreased by 20.6% year-over-year, from $2.02M to $1.61M.
- What is the long-term trend for Climb Bio, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Climb Bio, Inc.'s stock-based comp has grown at a 21.2% compound annual growth rate (CAGR), from $3.74M to $8.05M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Climb Bio, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude